Summary Using CM-1 antibody directed against the human p53 protein, high levels of mutant p53 protein expression were found in 12 out of 18 malignant choroidal melanomas. In contrast, we failed to observe elevated p53 expression, indicating the absence of p53 mutation in seven choroidal naevi, a potentially premalignant condition that can progress to form malignant melanoma. For two choroidal melanomas, we demonstrated that high levels of p53 protein were accompanied by exon 7 mutations. The mutations were found at codon 238, TGT-*TTT and codon 253, ACC-*AGC. These observations suggest that acquisition of abnormalities of the p53 gene may be an important step in the development of malignant melanoma.
Choroidal melanoma is the commonest intraocular malignancy in adults. It is classified on a histological basis into spindle cell, epithelioid, and mixed cell types. Prognosis of the disease is uncertain and metastasis, usually in the liver, can occur up to 16 years after the apparently successful removal of the eye (Willis, 1960; Egan et al., 1988) . Apart from some reports of melanomas developed from pre-existing naevi, which are benign pigmented spots in the choroid (Yanoff & Zimmerman, 1967) , the aetiology of the disease is unclear. One of the fundamental problems in the management of this disease is the lack of understanding of the biological factors that govern its behaviour. Unlike other tumours, including cutaneous melanoma, little research has been carried out to identify and analyse the role of oncogenes and tumour suppressor genes in the development and prognosis of choroidal melanoma.
Recent evidence suggests that mutation of the p53 suppressor gene is one of the commonest abnormalities found in human cancers (Levine et al., 1991; Caron de Fromental & Soussi, 1992) . This gene is located on the short arm of chromosome 17 and encodes a 53 kDa nuclear protein that appears to be involved in regulating the cell cycle. The normal p53 product has been shown to act as a tumour suppressor Baker et al., 1990a) , but various point mutations within the coding region of the gene inactivate or alter this function Finlay et al., 1989; Hinds et al., 1989; Baker et al., 1990a; Diller et al., 1990; Mercer et al., 1990) . Point mutations in the p53 gene increase the stability of its protein product and lead to an increase in the level of mutant protein present in the cell (Finlay et al., 1988) . This allows immunohistochemical techniques to be used to screen for p53 mutations, since the low levels of wild type protein normally present in cells cannot be detected by this method (Cattoretti et al., 1988; Van Den Berg et al., 1989; Bartek et al., 1990; Rodrigues et al., 1990; Gusterson et al., 1991 amplify exon 5; c and d to amplify exon 7; and e and f to amplify exon 8) and two units of Taq DNA polymerase. These exons were chosen because previous reports indicated that they account for the majority of mutations in the p53 gene in other classes of human tumours (Nigro et al., 1989) . Primers used were (location is given between brackets):
(a) 5' ATCTGTTCACTTGTGCCCTG 3' (intron 4); (b) 5' AACCAGCCCTGTCGTCTCTC 3' (intron 5); (c) 5' GCTTGCCACAGGTCTCCCCAA 3' (intron 6); (d) 5' AGGGGTCAGCGGCAAGCAGA 3' (intron 7); (e) 5' GGACCTGATTTCCTTACTGC 3' (intron 7); and (f) 5' CTTCTTTGGCTGGGGAGAGG 3' (intron 8). Primers a, c and e have a biotin residue on their 5' end. This was used to generate single stranded PCR products for direct sequencing. To do that, PCR products were purified by electrophoresis in 2% (w/v) low melting point agarose, and single stranded products prepared using Dynabeads coated with streptavidin. The PCR product was incubated with Dynabeads coated with streptavidin for 30 min, which were then washed with double distilled water. The DNA was washed twice with 0.15 N NaOH to allow the separation of the two strands of DNA, and the preparation of a single stranded product attached to the beads. The final single stranded product was sequenced using the dideoxy method as previously described (Sanger et al., 1977) .
Results
Using the CM-1 anti-human p53 antibody (Midgley et (Tables I and II ). An example of these studies is shown in Figure 2 . To Figure 3 . stained by the immunohistochemical technique. Staining was predominantly nuclear, though in some cases both nuclear and cytoplasmic staining was observed. Cytoplasmic staining has been observed in other studies Dr. D. Lane, personal communication). Iggo et al., 1990;  suggested that the cytoplasmic staining detected in small cell lung tumours may be due to the presence of very high levels of p53 protein and that this could be correlated with the poor prognosis of the tumour. Sequence analysis which was carried out on two positively and one negatively stained tissues showed the presence of point mutations at exon seven of the p53 gene in the two positively stained tissues, while the negatively stained tissue tested showed no mutation in the p53 gene. These point mutations occurred in a region of the p53 gene that is highly conserved across several different species (Soussi et al., 1990) and several human tumours have been shown to have point mutations in these codons (Hollstein et al., 1991) . When considered together, these observations show that a high proportion of choroidal melanomas exhibit p53 staining and that this over-expression of the p53 protein correlates with the presence of point mutations in the gene. Since premalignant choroidal naevi, some of which may progress into malignant melanomas (Yanoff & Zimmerman, 1967) , failed to exhibit mutant p53 protein expression, it appears that the acquisition of abnormalities in the p53 gene is specifically associated with malignant tumours of the choroid. It is therefore possible that p53 mutations could play an important role in the progression of some naevi to malignancy. This hypothesis is supported by similar findings in other human tumours, such as colorectal carcinomas, in which it was found (Baker et al., 1990b ) that both mutations and allelic losses of chromosome 17 generally occur near the transition from benign adenomas to malignant carcinomas.
We could not make a clear correlation between the presence of p53 mutations and the prognosis of the disease, as all the tissues used in this study were from recently enucleated eyes, however, the examination of a large number of melanoma tissues may paint a clearer picture regarding the relevance of p53 mutations to the prognosis of the disease. 
